ClinicalTrials.gg
CompletedNCT04819269Updated Feb 20, 2024

Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome

A Phase 3 interventional study of Tivanisiran sodium ophthalmic solution and Vehicle ophthalmic solution in Dry Eye Disease and Sjögren Syndrome, sponsored by Sylentis, S.A.. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 3, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 544 studies in Dry Eye Syndromes with a site in United States — 52 open to participants now, 63 under way, 3 of them phase 3. Dry Eye Syndromes · United States.

Enrollment
105th of 473
203 · median 60
Started
2021
with 38 others
Phase 3
77 of 544
1 open now
Registered
366th of 544
by date

Among the 544 studies in Dry Eye Syndromes with a site in United States, this one is the 105th largest by enrollment of the 473 interventional ones that give a count, is one of 39 that started in 2021, is one of 77 in phase 3, and was the 366th registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

52 of the 544 studies in Dry Eye Syndromes with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 544 studies in Dry Eye Syndromes with a site in United States, or all of them as a file.
02

Study summary

This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to Sjögren's Syndrome.

03

Conditions studied

  • Dry Eye Disease
  • Sjögren Syndrome

Keywords

  • oligonucleotide
  • siRNA
  • keratoconjunctivitis sicca
  • SYL1001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a male or a female aged ≥ 18 years
  • Have given their written consent to participate in the study
  • Use of artificial tears (AT), autologous serum or specific dry eye medications during the last 6 months prior to the selection
  • Willing to not use AT or autologous serum for the study duration
  • VAS scale for Dry Eye Symptom Score ≥ 40
  • Total CFS ≥ 5
  • Schirmer's test with anesthesia \< 10 mm/5min
  • Patients with Sjögren Syndrome

Exclusion criteria

Exclusion Criteria:

  • Any concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications at the time of entry into the study
  • Use of contact lenses during the study
  • Significant Eye diseases according to investigator's opinion
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
203 participants (actual)

Study arms

  • Active comparator
    Tivanisiran sodium ophthalmic solution

    Drug: Tivanisiran sodium ophthalmic solution

  • Placebo comparator
    Vehicle ophthalmic solution

    Drug: Vehicle ophthalmic solution

Interventions

  • DrugTivanisiranStudies of TivanisiranTivanisiran pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 drop in the affected eye(s) once daily

  • DrugVehicle ophthalmic solution

    1 drop in the affected eye(s) once daily

06

What researchers measure

Primary outcomes

  1. Change from baseline in Corneal Fluorescein Staining (CFS) scale [0-3]. Higher scores mean disease worsening.

    Time frame: 85 days

  2. Change from baseline in Dry Eye Symptom scale [0-100]. Higher scores mean disease worsening.

    Time frame: 85 days

07

Study locations

46 sites
  • Sylentis Investigative Site
    Birmingham, Alabama 35294, United States
  • Sylentis Investigative Site
    Dothan, Alabama 36301, United States
  • Sylentis Investigative Site
    Scottsdale, Arizona 85254, United States
  • Sylentis Investigative Site
    Garden Grove, California 92843, United States
  • Sylentis Investigative Site
    Glendale, California 91204, United States
  • Sylentis Investigative Site
    Los Angeles, California 90013, United States
  • Sylentis Investigative Site
    Newport Beach, California 92663, United States
  • Sylentis Investigative Site
    Rancho Cordova, California 95670, United States
  • Sylentis Investigative Site
    San Diego, California 92122, United States
  • Sylentis Investigative Site
    Torrance, California 90505, United States
  • Sylentis Investigative Site
    Aurora, Colorado 80045, United States
  • Sylentis Investigative Site
    Colorado Springs, Colorado 80907, United States
  • Sylentis Investigative Site
    Littleton, Colorado 80120, United States
  • Sylentis Investigative Site
    Jacksonville, Florida 32256, United States
  • Sylentis Investigative Site
    Largo, Florida 33773, United States
  • Sylentis Investigative Site
    Miami, Florida 33136, United States
  • Sylentis Investigative Site
    Ormond Beach, Florida 32174, United States
  • Sylentis Investigative Site
    Tampa, Florida 33603, United States
  • Sylentis Investigative Site
    Atlanta, Georgia 30339, United States
  • Sylentis Investigative Site
    Morrow, Georgia 30260, United States
  • Sylentis Investigative Site
    Carmel, Indiana 46290, United States
  • Sylentis Investigative Site
    Waltham, Massachusetts 02451, United States
  • Sylentis Investigative Site
    Ypsilanti, Michigan 48197, United States
  • Sylentis Investigative Site
    Kansas City, Missouri 64111, United States
  • Sylentis Investigative Site
    Saint Louis, Missouri 63131, United States
  • Sylentis Investigative Site
    Washington, Missouri 63090, United States
  • Sylentis Investigative Site
    Asheville, North Carolina 28803, United States
  • Sylentis Investigative Site
    High Point, North Carolina 27262, United States
  • Sylentis Investigative Site
    Fargo, North Dakota 58103, United States
  • Sylentis Investigative Site
    Cleveland, Ohio 44115, United States
  • Sylentis Investigative Site
    Columbus, Ohio 43215, United States
  • Sylentis Investigative Site
    Cranberry Township, Pennsylvania 16066, United States
  • Sylentis Investigative Site
    Rapid City, South Dakota 57701, United States
  • Sylentis Investigative Site
    Memphis, Tennessee 38103, United States
  • Sylentis Investigative Site
    Nashville, Tennessee 37215, United States
  • Sylentis Investigative Site
    El Paso, Texas 79902, United States
  • Sylentis Investigative Site
    Houston, Texas 77030, United States
  • Sylentis Investigative Site
    Houston, Texas 77034, United States
  • Sylentis Investigative Site
    Falls Church, Virginia 22042, United States
  • Sylentis Investigative Site
    Pamplona, Navarra 31008, Spain
  • Sylentis Investigative Site
    Barcelona, 08022, Spain
  • Sylentis Investigative Site
    Madrid, 28034, Spain
  • Sylentis Investigative Site
    Madrid, 28040, Spain
  • Sylentis Investigative Site
    Sevilla, 41009, Spain
  • Sylentis Investigative Sites
    Valladolid, 47003, Spain
  • Sylentis Investigative Site
    Zaragoza, 50004, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Dec 2023, 30 months.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 30 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2021
First posted
Mar 26, 2021
StartActual
May 25, 2021
Primary completionActual
Dec 11, 2023
CompletionActual
Dec 11, 2023
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04819269
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
May 25, 2021
Primary completion
Dec 11, 2023
Completion
Dec 11, 2023
Last update
Feb 20, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tivanisiran

Start the discussion